Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UNITED THERAPEUTICS (UTHR) Shares Outstanding (Weighted Average): 2009-2025

Historic Shares Outstanding (Weighted Average) for UNITED THERAPEUTICS (UTHR) over the last 17 years, with Sep 2025 value amounting to $45.2 million.

  • UNITED THERAPEUTICS's Shares Outstanding (Weighted Average) rose 1.65% to $45.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.2 million, marking a year-over-year increase of 1.65%. This contributed to the annual value of $44.6 million for FY2024, which is 5.00% down from last year.
  • UNITED THERAPEUTICS's Shares Outstanding (Weighted Average) amounted to $45.2 million in Q3 2025, which was up 0.27% from $45.1 million recorded in Q2 2025.
  • In the past 5 years, UNITED THERAPEUTICS's Shares Outstanding (Weighted Average) registered a high of $47.1 million during Q1 2024, and its lowest value of $44.4 million during Q2 2024.
  • In the last 3 years, UNITED THERAPEUTICS's Shares Outstanding (Weighted Average) had a median value of $45.2 million in 2025 and averaged $45.7 million.
  • Per our database at Business Quant, UNITED THERAPEUTICS's Shares Outstanding (Weighted Average) climbed by 3.42% in 2023 and then declined by 5.32% in 2024.
  • Over the past 5 years, UNITED THERAPEUTICS's Shares Outstanding (Weighted Average) (Quarterly) stood at $45.0 million in 2021, then increased by 1.20% to $45.6 million in 2022, then rose by 3.11% to $47.0 million in 2023, then declined by 5.00% to $44.6 million in 2024, then rose by 1.65% to $45.2 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $45.2 million for Q3 2025, versus $45.1 million for Q2 2025 and $44.9 million for Q1 2025.